Precision Diagnostics by Affinity-Mass Spectrometry: A Novel Approach for Fetal Growth Restriction Screening during Pregnancy
暂无分享,去创建一个
Michael O. Glocker | Werner Rath | M. Glocker | W. Rath | Charles A. Okai | Manuela Russ | Manja Wölter | Kristin Andresen | Ulrich Pecks | U. Pecks | C. Okai | M. Russ | M. Wölter | K. Andresen
[1] Jason Gardosi,et al. Fetal growth screening by fundal height measurement. , 2009, Best practice & research. Clinical obstetrics & gynaecology.
[2] M. Glocker,et al. Multiparametric Analysis of Mass Spectrometry‐Based Proteome Profiling in Gestation‐Related Diseases , 2014 .
[3] Z. Alfirevic,et al. Placental Growth Factor informed management of suspected pre-eclampsia or fetal growth restriction: The MAPPLE cohort study. , 2017, Pregnancy hypertension.
[4] M. Glocker,et al. Early risk prognosis of free-flap transplant failure by quantitation of the macrophage colony-stimulating factor in patient plasma using 2-dimensional liquid-chromatography multiple reaction monitoring-mass spectrometry , 2016, Medicine.
[5] M. Glocker,et al. Mass spectrometric profiling of cord blood serum proteomes to distinguish infants with intrauterine growth restriction from those who are small for gestational age and from control individuals. , 2014, Translational research : the journal of laboratory and clinical medicine.
[6] M. Glocker,et al. Angiogenic factors and acute-phase proteins in serum samples of preeclampsia and HELLP patients: a matched-pair analysis , 2013, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.
[7] K. Hecher,et al. Intrauterine Growth Restriction. Guideline of the German Society of Gynecology and Obstetrics (S2k-Level, AWMF Registry No. 015/080, October 2016) , 2017, Geburtshilfe und Frauenheilkunde.
[8] Hans-Jürgen Thiesen,et al. Towards a proteome signature for invasive ductal breast carcinoma derived from label-free nanoscale LC-MS protein expression profiling of tumorous and glandular tissue , 2009, Analytical and bioanalytical chemistry.
[9] B. Reiser,et al. Estimation of the area under the ROC curve , 2002, Statistics in medicine.
[10] F. P. Hadlock,et al. Estimation of fetal weight with the use of head, body, and femur measurements--a prospective study. , 1985, American journal of obstetrics and gynecology.
[11] E. Gratacós,et al. Update on the Diagnosis and Classification of Fetal Growth Restriction and Proposal of a Stage-Based Management Protocol , 2014, Fetal Diagnosis and Therapy.
[12] Edgar Erdfelder,et al. G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences , 2007, Behavior research methods.
[13] C. Fitzner,et al. Maternal and fetal cord blood lipids in intrauterine growth restriction , 2012, Journal of perinatal medicine.
[14] Y. Takwoingi,et al. Biochemical tests of placental function versus ultrasound assessment of fetal size for stillbirth and small-for-gestational-age infants. , 2019, The Cochrane database of systematic reviews.
[15] P. Revesz. Interpolation and Approximation , 2010 .
[16] H. Zeisler,et al. New Gestational Phase–Specific Cutoff Values for the Use of the Soluble fms-Like Tyrosine Kinase-1/Placental Growth Factor Ratio as a Diagnostic Test for Preeclampsia , 2014, Hypertension.
[17] A. Sinaiko,et al. Plasma protein profiling: Unique and stable features of individuals , 2005, Proteomics.
[18] W. Youden,et al. Index for rating diagnostic tests , 1950, Cancer.
[19] M. Glocker,et al. Cryodetector mass spectrometry profiling of plasma samples for HELLP diagnosis: An exploratory study , 2005, Proteomics.
[20] P. Sheehan,et al. Introduction of a customised growth chart protocol increased detection of small for gestational age pregnancies in a tertiary Melbourne hospital , 2018, The Australian & New Zealand journal of obstetrics & gynaecology.
[21] K. Lim,et al. Angiogenic Factors and the Risk of Adverse Outcomes in Women With Suspected Preeclampsia , 2012, Circulation.
[22] Mina Abbassi-Ghanavati,et al. Pregnancy and Laboratory Studies: A Reference Table for Clinicians , 2009, Obstetrics and gynecology.
[23] L. Mackillop,et al. Diagnostic Accuracy of Placental Growth Factor in Women With Suspected Preeclampsia: A Prospective Multicenter Study , 2013, Circulation.
[24] J. Gardosi. Customized charts and their role in identifying pregnancies at risk because of fetal growth restriction. , 2014, Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC.
[25] Yoav Benjamini,et al. Opening the Box of a Boxplot , 1988 .
[26] S. Brennecke,et al. Predictive Value of the sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia. , 2016, The New England journal of medicine.
[27] M. Glocker,et al. Proteoform profiling of peripheral blood serum proteins from pregnant women provides a molecular IUGR signature. , 2016, Journal of proteomics.
[28] M. Glocker,et al. Multifactorial analysis of affinity-mass spectrometry data from serum protein samples: A strategy to distinguish patients with preeclampsia from matching control individuals , 2010, Journal of the American Society for Mass Spectrometry.
[29] Francesc Figueras,et al. Intrauterine growth restriction: new concepts in antenatal surveillance, diagnosis, and management. , 2011, American journal of obstetrics and gynecology.
[30] M. Glocker,et al. A proteome signature for intrauterine growth restriction derived from multifactorial analysis of mass spectrometry‐based cord blood serum profiling , 2012, Electrophoresis.
[31] C. Metz. Basic principles of ROC analysis. , 1978, Seminars in nuclear medicine.
[32] K. Schulz,et al. Compared to what? Finding controls for case-control studies , 2005, The Lancet.
[33] P. Czernichow,et al. International Small for Gestational Age Advisory Board consensus development conference statement: management of short children born small for gestational age, April 24-October 1, 2001. , 2003, Pediatrics.
[34] S. Chauhan,et al. Screening for Fetal Growth Restriction , 2006, Clinical obstetrics and gynecology.
[35] R. Nelson,et al. Detection of novel truncated forms of human serum amyloid A protein in human plasma , 2003, FEBS letters.
[36] A. Galindo,et al. sFlt‐1/PlGF ratio and timing of delivery in early‐onset fetal growth restriction with antegrade umbilical artery flow , 2019, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.
[37] M. Greiner,et al. Principles and practical application of the receiver-operating characteristic analysis for diagnostic tests. , 2000, Preventive veterinary medicine.
[38] W. März,et al. Low density lipoprotein (LDL) subfractions during pregnancy: accumulation of buoyant LDL with advancing gestation. , 2000, The Journal of clinical endocrinology and metabolism.
[39] M. Gilbert,et al. MGMT Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide: A Pooled Analysis of Four Clinical Trials , 2018, Clinical Cancer Research.
[40] M. Glocker,et al. Mass Spectrometric Characterization of Protein Structure Details Refines the Proteome Signature for Invasive Ductal Breast Carcinoma , 2011, Journal of the American Society for Mass Spectrometry.
[41] M. Díaz,et al. Postnatal Anthropometric and Body Composition Profiles in Infants with Intrauterine Growth Restriction Identified by Prenatal Doppler , 2016, PloS one.
[42] M. Glocker,et al. Maternal Apolipoprotein B100 Serum Levels are Diminished in Pregnancies with Intrauterine Growth Restriction and Differentiate from Controls , 2018, Proteomics. Clinical applications.
[43] Thomas Wetter,et al. Feature construction can improve diagnostic criteria for high-dimensional metabolic data in newborn screening for medium-chain acyl-CoA dehydrogenase deficiency. , 2007, Clinical chemistry.
[44] J. Hutcheon,et al. Placental growth factor as a marker of fetal growth restriction caused by placental dysfunction. , 2016, Placenta.
[45] O S Miettinen,et al. The "case-control" study: valid selection of subjects. , 1985, Journal of chronic diseases.
[46] M. Glocker,et al. Comparison of blood serum protein analysis by MALDI-MS from either conventional frozen samples or storage disc-deposited samples: A study with human serum from pregnant donors and from patients with intrauterine growth restriction , 2019, European journal of mass spectrometry.
[47] H. Zeeb,et al. Care-Related and Maternal Risk Factors Associated with the Antenatal Nondetection of Intrauterine Growth Restriction: A Case-Control Study from Bremen, Germany , 2017, BioMed Research International.
[48] M. Mongelli,et al. Screening for Fetal Growth Restriction: A Mathematical Model of the Effect of Time Interval and Ultrasound Error , 1998, Obstetrics and gynecology.
[49] Jonathan D. Stallings,et al. Longitudinal Analysis of Maternal Plasma Apolipoproteins in Pregnancy: A Targeted Proteomics Approach* , 2012, Molecular & Cellular Proteomics.
[50] I. Scripcariu,et al. A CASE-CONTROL STUDY , 2009 .